Pharma major plummets over 10% after third trial disappointment in a week

Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.

CNBC • 6 hours ago

Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial

The drug candidate was one of three therapies the Swiss pharmaceutical company added to its pipeline through its $12 billion acquisition of Avidity Biosciences.

WSJ • 8 hours ago

Novartis announces trial setback on del-desiran drug

Swiss drugmaker Novartis on Tuesday said a late-stage study assessing drug ​del-desiran's impact on myotonic dystrophy, a ‌form of muscle wasting, had not met its target on a key metric, but reaffirmed ​its sales guidance through 2030.

Reuters • 7 hours ago

Novartis stock falls 10% after second drug setback in a week; analyst cuts PT

Novartis shares fell sharply on Tuesday after the Swiss drugmaker said its experimental treatment for myotonic dystrophy failed in a late-stage clinical trial, marking another setback for a pipeline that investors had been counting on to drive future growth. The stock fell about 10% following the announcement and has now lost more than 14% over the past five trading sessions.

Invezz • 5 hours ago

Cholesterol drug setback casts doubt over multibillion-dollar race

Novartis' pelacarsen failed to reduce cardiovascular events despite lowering the harmful cholesterol Lp(a). The setback raises uncertainty for rival experimental Lp(a) drugs from Amgen and Eli Lilly.

CNBC • 8 hours ago

Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners

On Tuesday, Novartis AG (NYSE:NVS) stock witnessed one of the sharpest single-day declines for the company in recent history.

Benzinga • an hour ago

Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling over 400 points on Tuesday.

Benzinga • an hour ago

Intel, Amgen, Novartis, Bloom Energy, and More Stocks That Explain Today's Market

AI stocks rise despite the market's inflation worries, but Amgen falls following Swiss drugmaker Novartis' disappointing trial data.

Barrons • 2 hours ago

Novartis shares down as failed cholesterol drug study increases pipeline pressure

Shares of Novartis fell 3.3% on Monday morning after its ​cholesterol drug failed in a ‌closely watched study, casting fresh doubt on the therapeutic approach and ​raising the stakes for the ​Swiss drugmaker's upcoming data for ⁠a gene therapy.

Reuters • Sep 7, 2026

Novartis Shares Fall After Heart Drug Misses Target in Late-Stage Trial

The company said the late-stage study for its pelacarsen drug missed its primary objective of reducing the risk of cardiovascular events like death, heart attack and stroke compared with placebo.

WSJ • Sep 7, 2026